HBV Treatment
EASL 2015: Using Interferon with Hepatitis B Antivirals Raises Likelihood of HBsAg Loss
- Details
- Category: HBV Treatment
- Published on Tuesday, 09 June 2015 00:00
- Written by Liz Highleyman
Treating chronic hepatitis B with tenofovir plus pegylated interferon for 48 weeks resulted in a higher rate of hepatitis B surface antigen (HBsAg) clearance than either drug taken alone, though the response rate was still just 9%, according to a study presented at the recent European Association for the Study of the Liver (EASL) 50th International Liver Congress in Vienna. Other researchers reported that adding 48 weeks of interferon to nucleoside/nucleotide therapy increased the rate of HBsAg loss to about the same level, and switching to interferon may be effective for selected patients.
EASL 2015: Stopping Tenofovir is Safe for Hepatitis B Patients on Long-term Therapy
- Details
- Category: HBV Treatment
- Published on Thursday, 28 May 2015 00:00
- Written by Liz Highleyman
Most hepatitis B patients who stopped taking tenofovir (Viread) after more than 3 years on treatment had good outcomes, according to a presentation at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Although all patients who stopped tenofovir saw their HBV viral load rise, most maintained normal ALT levels and only a few needed to restart therapy.
EASL 2015: Expanded Vaccination and Treatment Could Help Eliminate Hepatitis B Worldwide
- Details
- Category: HBV Treatment
- Published on Friday, 24 April 2015 00:00
- Written by Liz Highleyman
While universal infant hepatitis B virus (HBV) vaccination has already led to major advances in reducing new infections in some settings, further expansion of prevention and treatment are needed to significantly reduce HBV transmission and liver disease mortality, according to an analysis presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress this week in Vienna.
EASL 2015: Nucleic Acid Polymer REP 2139-Ca Shows Promise Against Hepatitis B and Delta Viruses
- Details
- Category: Experimental HBV Drugs
- Published on Monday, 11 May 2015 00:00
- Written by Liz Highleyman
The nucleic acid-based polymer REP 2139-Ca lowered hepatitis B surface antigen (HBsAg) levels and significantly reduced hepatitis B and hepatitis delta viral loads when combined with immunotherapy, according to presentations at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.
Global Hepatitis B Epidemic Treatable at Cost of Just $36 per Patient per Year
- Details
- Category: HBV Treatment
- Published on Wednesday, 22 April 2015 00:00
- Written by Michael Carter
Large-scale production of generic entecavir (Baraclude) could cut the cost of first-line hepatitis B virus (HBV) therapy to just $36 per patient per year, according to a study published in the online edition of the Journal of Virus Eradication. The authors believe that this price could facilitate low-cost global therapy for hepatitis B. The cost of scaled-up generic production of entecavir was shown to be significantly cheaper than that associated with alternative therapies, including tenofovir (Viread).
More Articles...
- World Health Organization Issues First Hepatitis B Prevention and Treatment Guidelines
- 11. Hepatitis B: Interferon Boosts Cure Rate, Tenofovir Works Long-Term
- AASLD 2014: Experimental siRNA Therapy Lowers HBsAg Levels in Hepatitis B Patients
- AASLD 2014: Entecavir and Tenofovir Work Well for People with Resistant Hepatitis B Virus
Web Design and Development by